Ionis Pharmaceuticals, Inc.

BMV:IONS * Stock Report

Market Cap: Mex$115.7b

Ionis Pharmaceuticals Valuation

Is IONS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IONS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IONS * (MX$720.55) is trading above our estimate of fair value (MX$43.7)

Significantly Below Fair Value: IONS * is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IONS *?

Key metric: As IONS * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IONS *. This is calculated by dividing IONS *'s market cap by their current revenue.
What is IONS *'s PS Ratio?
PS Ratio7x
SalesUS$803.07m
Market CapUS$5.58b

Price to Sales Ratio vs Peers

How does IONS *'s PS Ratio compare to its peers?

The above table shows the PS ratio for IONS * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.9x
LAB B Genomma Lab Internacional. de
1.4x9.9%Mex$24.6b
6990 Sichuan Kelun-Biotech Biopharmaceutical
20.4x24.2%HK$43.7b
002007 Hualan Biological Engineering
6.2x17.5%CN¥30.6b
ABCM Abcam
11.6x13.0%US$5.5b
IONS * Ionis Pharmaceuticals
7x21.9%Mex$5.6b

Price-To-Sales vs Peers: IONS * is good value based on its Price-To-Sales Ratio (7x) compared to the peer average (10.2x).

Price to Sales Ratio vs Industry

How does IONS *'s PS Ratio compare vs other companies in the Global Biotechs Industry?

273 CompaniesPrice / SalesEstimated GrowthMarket Cap
No. of Companies273PS01632486480+
273 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IONS * is good value based on its Price-To-Sales Ratio (7x) compared to the Global Biotechs industry average (9x).

Price to Sales Ratio vs Fair Ratio

What is IONS *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IONS * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IONS *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IONS * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
Mex$1,241.87
0%
16.8%Mex$1,559.48Mex$748.87n/a25
Nov ’25n/a
Mex$1,208.41
0%
16.3%Mex$1,590.25Mex$717.55n/a25
Oct ’25n/a
Mex$1,258.97
0%
16.2%Mex$1,647.27Mex$743.28n/a25
Sep ’25n/a
Mex$1,218.45
0%
16.0%Mex$1,588.17Mex$716.61n/a25
Aug ’25n/a
Mex$1,153.16
0%
18.4%Mex$1,539.31Mex$619.48n/a25
Jul ’25n/a
Mex$1,077.33
0%
18.8%Mex$1,509.75Mex$607.58n/a23
Jun ’25n/a
Mex$979.21
0%
19.8%Mex$1,385.62Mex$557.63n/a23
May ’25n/a
Mex$995.62
0%
20.5%Mex$1,455.78Mex$496.68n/a24
Apr ’25n/a
Mex$957.55
0%
24.2%Mex$1,435.06Mex$489.61n/a22
Mar ’25n/a
Mex$964.08
0%
23.8%Mex$1,453.00Mex$495.73n/a22
Feb ’25n/a
Mex$960.55
0%
23.9%Mex$1,452.35Mex$478.42n/a22
Jan ’25n/a
Mex$932.20
0%
24.8%Mex$1,444.03Mex$475.68n/a22
Dec ’24n/a
Mex$941.55
0%
25.6%Mex$1,471.66Mex$484.78n/a22
Nov ’24n/a
Mex$961.57
0%
28.9%Mex$1,588.71Mex$451.34n/a22
Oct ’24n/a
Mex$914.63
0%
31.0%Mex$1,544.86Mex$438.88n/a22
Sep ’24n/a
Mex$868.51
0%
33.0%Mex$1,499.73Mex$426.06n/a21
Aug ’24n/a
Mex$857.29
0%
32.5%Mex$1,473.51Mex$401.87n/a21
Jul ’24n/a
Mex$856.23
0%
33.5%Mex$1,506.63Mex$445.14n/a21
Jun ’24n/a
Mex$870.67
0%
33.6%Mex$1,545.28Mex$456.56n/a21
May ’24n/a
Mex$879.50
0%
36.6%Mex$1,660.37Mex$433.14n/a20
Apr ’24n/a
Mex$903.30
0%
36.8%Mex$1,713.13Mex$446.90n/a20
Mar ’24n/a
Mex$920.68
0%
35.2%Mex$1,693.71Mex$441.84n/a20
Feb ’24n/a
Mex$962.10
0%
33.9%Mex$1,732.31Mex$451.91n/a20
Jan ’24n/a
Mex$1,003.67
0%
33.6%Mex$1,807.32Mex$471.48n/a21
Dec ’23n/a
Mex$1,000.25
0%
32.8%Mex$1,774.69Mex$462.96n/a21
Nov ’23n/a
Mex$1,015.99
0%
34.4%Mex$1,827.80Mex$437.08n/a21

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

CSPC Pharmaceutical Group

HK$69.4b

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.

1093 N

HK$15.69

7D

0%

1Y

-27.0%

Exact Sciences

US$13.1b

Provides cancer screening and diagnostic test products in the United States and internationally.

EXAS *

US$872.00

7D

0%

1Y

n/a

Novartis

CHF 183.8b

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

NOVN N

CHF 2,236.00

7D

0%

1Y

n/a